Tolerability of treatment with pirfenidone or nintedanib for pulmonary fibrosis in the real world

被引：4
|
作者：
Ogura, Takashi [1 ]
Kitamura, Hideya [1 ]
机构：
[1] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan
来源：
RESPIROLOGY | 2017年 / 22卷 / 06期
关键词：
idiopathic pulmonary fibrosis; nintedanib; pirfenidone; therapeutics; tolerability; RANDOMIZED-TRIALS; SAFETY;
D O I：
10.1111/resp.13059
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：1051 / 1052
页数：2
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE VERSUS NINTEDANIB ON THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
    Ho, R.
    Rufino, C.
    Lisondo, C.
    Alves, M.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A893 - A894
  • [42] Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan
    Hisata, Shu
    Bando, Masashi
    Homma, Sakae
    Kataoka, Kensuke
    Ogura, Takashi
    Izumi, Shinyu
    Sakamoto, Susumu
    Watanabe, Kizuku
    Saito, Yoshinobu
    Shimizu, Yasuo
    Kato, Motoyasu
    Nishioka, Yasuhiko
    Hara, Hiromichi
    Waseda, Yuko
    Tanino, Yoshinori
    Yatera, Kazuhiro
    Hashimoto, Seishu
    Mukae, Hiroshi
    Inase, Naohiko
    [J]. RESPIRATORY INVESTIGATION, 2021, 59 (06) : 819 - 826
  • [43] Real-life Data on the Safety and Tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) Patients: A Single-Centre Study
    Thong, L.
    Bowen, B.
    Henry, M. T.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 1) : S28 - S29
  • [44] Safety and Tolerability of Combination Therapy with Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis: A Multicenter, Retrospective, Observational Study in Japan
    Hisata, Shu
    Bando, Masashi
    Homma, Sakae
    Kataoka, Kensuke
    Ogura, Takashi
    Izumi, Shinyu
    Sakamoto, Susumu
    Saito, Yoshinobu
    Watanabe, Kizuku
    Shimizu, Yasuo
    Kato, Motoyasu
    Inase, Naohiko
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [45] Long-Term Treatment with Nintedanib for Idiopathic Pulmonary Fibrosis in a Real-World Setting
    Kato, M.
    Sasaki, S.
    Arai, Y.
    Motomura, H.
    Sumiyoshi, I.
    Ochi, Y.
    Watanabe, J.
    Ihara, H.
    Togo, S.
    Takahashi, K.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [46] Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
    Brunnemer, Eva
    Waelscher, Julia
    Tenenbaum, Svenja
    Hausmanns, Julia
    Schulze, Karen
    Seiter, Marianne
    Heussel, Claus Peter
    Warth, Arne
    Herth, Felix J. F.
    Kreuter, Michael
    [J]. RESPIRATION, 2018, 95 (05) : 301 - 309
  • [47] Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis
    Gulati, Swati
    Luckhardt, Tracy R.
    [J]. DRUG HEALTHCARE AND PATIENT SAFETY, 2020, 12 : 85 - 94
  • [48] NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS: SAFETY AND TOLERABILITY
    Glaspole, I
    Lancaster, L.
    Hernandez, P.
    Inoue, Y.
    Wachtlin, D.
    Loaiza, L.
    Conoscenti, C.
    Quaresma, M.
    Stowasser, S.
    Richeldi, L.
    [J]. RESPIROLOGY, 2019, 24 : 34 - 34
  • [49] Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
    Di Martino, Enrica
    Provenzani, Alessio
    Vitulo, Patrizio
    Polidori, Piera
    [J]. ANNALS OF PHARMACOTHERAPY, 2021, 55 (06) : 723 - 731
  • [50] Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study
    Yin, Lorraine Thong Wan
    Bowen, Bernadette
    Henry, Micahel
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 58
12345